Ultrabright Plasmonic-Fluor Nanosensor-Enabled Noninvasive Management of Pediatric Nephrotic Syndrome
超亮等离子体荧光纳米传感器支持小儿肾病综合征的无创治疗
基本信息
- 批准号:10593497
- 负责人:
- 金额:$ 23.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-06 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcuteAcute Renal Failure with Renal Papillary NecrosisAdoptedAffectAlbuminsAngiotensin-Converting Enzyme InhibitorsAntibodiesBindingBiological AssayBloodBlood Urea NitrogenBlood VolumeCaringChildChildhoodClinicalClinical ManagementCoupledCreatinineDataDecentralizationDermalDetectionDevelopmentDiagnosticDiseaseDiureticsEarly DiagnosisEnd stage renal failureEnzyme Inhibitor DrugsExhibitsFluoroimmunoassayFutureGoalsHealthcare SystemsHomeHumanHypoalbuminemiaImmunoassayImmunosuppressive AgentsIn SituInfantInheritedIntercellular FluidKidneyKidney DiseasesLeadMethodsModelingMonitorMusNephrologyNephrotic SyndromeNewborn InfantPain FreePainlessPatientsPharmaceutical PreparationsPhasePopulationPre-Clinical ModelProteinsProteinuriaPublic HealthReadingRenal functionReproducibilityResearchSamplingSerumSerum AlbuminSourceSteroid-resistant idiopathic nephrotic syndromeSuctionTechniquesTechnologyTestingTherapeutic immunosuppressionThromboembolismTranslationsUrineVacuumVenipuncturesacute toxicityafferent nervebaseclinical applicationclinical careclinically significantdiagnostic platformdiagnostic toolexperiencefollow-upimprovedinfection riskinnovationkidney dysfunctionminimally invasivemouse modelnanolabelnanosensorsneonatenephrotoxicitynon-invasive monitornovelnovel diagnosticspediatric patientspersonalized careplasmonicspoint of carepoint-of-care diagnosticssmall moleculetechnology validationtranslational studytreatment response
项目摘要
Pediatric nephrotic syndrome (NS), characterized by proteinuria, hypoalbuminemia and progressive loss of kidney function, is a debilitating childhood kidney disease. In addition, steroid-resistant NS, accounting for about 10% of end- stage kidney disease in the pediatric population, may require long-term use of immunosuppressants that can cause nephrotoxicity. The daunting difficulty in pediatric venipuncture, as well as the small volume limit of maximum blood draw allowed for a single draw and within 2 months, especially in neonates, infants and young children, has limited close monitoring of kidney function in the active phase of NS. Moreover, urine dipstick test, as a semi-quantitative and not- always-reliable assay, is a crude way of evaluating the treatment response. It is also unable to assess the kidney function that may be compromised by volume contraction, routine use of diuretics and angiotensin-converting enzyme inhibitors, and drug-induced renal toxicity acutely. Thus, development of an innovative, pain-free and volume extraction-free, and highly sensitive biodiagnostic platform is imperative to improve the clinical care for pediatric NS patients.
Bioanalyte-rich dermal interstitial fluid (ISF) provides a novel opportunity to achieve painless and effective biodiagnostic technologies. However, the clinical utility of ISF is limited by the current technology. Our goal is to develop our newly invented ultrabright plasmonic-fluor (PF)-enabled microneedle (MN) technology (PF-MN) as an ultrasensitive and minimally-invasive diagnostic tool for rapid sampling and quantification of ISF blood urea nitrogen (BUN) and creatinine (Cr) in point-of-care settings and at home. To accomplish our research goals, we will utilize a highly reproducible hereditary NS mouse model. In this preclinical model, we aim to determine concentrations of BUN and Cr in the dermal ISF by using PF-enhanced competitive immunoassay performed on MN. Furthermore, we will correlate their concentrations derived from MN-sampled ISF, extracted ISF and serum.
A successful completion of our pioneering proposal may lead to a paradigm-shift in the newborn and pediatric diagnostics. It will also pave the way for future translational study in pediatric NS patients.
小儿肾病综合征(NS)是一种使人衰弱的儿童肾脏疾病,以蛋白尿、低白蛋白血症和进行性肾功能丧失为特征。此外,约占儿科终末期肾病10%的类固醇耐药NS可能需要长期使用免疫抑制剂,这可能导致肾毒性。小儿静脉穿刺难度大,单次及2个月内最大采血量限制小,特别是新生儿、婴幼儿,限制了NS活动期肾功能的密切监测。此外,尿试纸试验作为一种半定量且不总是可靠的试验,是一种评估治疗反应的粗糙方法。它也无法评估可能因体积收缩、常规使用利尿剂和血管紧张素转换酶抑制剂以及药物引起的急性肾毒性而损害的肾功能。因此,开发一种创新的、无痛的、无体积提取的、高灵敏度的生物诊断平台是提高小儿神经痛患者临床护理水平的必要条件。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ying Maggie Chen其他文献
Beyond Redox Regulation: Novel Roles of TXNIP in the Pathogenesis and Therapeutic Targeting of Kidney Disease
超越氧化还原调节:硫氧还蛋白相互作用蛋白在肾脏疾病发病机制及治疗靶点中的新作用
- DOI:
10.1016/j.ajpath.2024.12.011 - 发表时间:
2025-04-01 - 期刊:
- 影响因子:3.600
- 作者:
Chuang Li;Yili Fang;Ying Maggie Chen - 通讯作者:
Ying Maggie Chen
Ying Maggie Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ying Maggie Chen', 18)}}的其他基金
PODOCYTE ENDOPLASMIC RETICULUM STRESS AND NEPHROTIC SYNDROME
足细胞内质网应激与肾病综合征
- 批准号:
9238166 - 财政年份:2017
- 资助金额:
$ 23.58万 - 项目类别:
PODOCYTE ENDOPLASMIC RETICULUM STRESS AND NEPHROTIC SYNDROME
足细胞内质网应激与肾病综合征
- 批准号:
10161772 - 财政年份:2017
- 资助金额:
$ 23.58万 - 项目类别:
PHARMACOLOGICAL RESCUE OF MUTANT LAMININ IN NEPHROTIC SYNDROME
突变层粘连蛋白对肾病综合征的药理学拯救
- 批准号:
8953410 - 财政年份:2015
- 资助金额:
$ 23.58万 - 项目类别:
PHARMACOLOGICAL RESCUE OF MUTANT LAMININ IN NEPHROTIC SYNDROME
突变层粘连蛋白对肾病综合征的药理学拯救
- 批准号:
9110975 - 财政年份:2015
- 资助金额:
$ 23.58万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 23.58万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 23.58万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 23.58万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 23.58万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 23.58万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 23.58万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 23.58万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 23.58万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 23.58万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 23.58万 - 项目类别:
Operating Grants